Cargando…

Repurposing drugs to treat neurological diseases

Detalles Bibliográficos
Autores principales:	Massey, T. H., Robertson, N. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808092/ https://www.ncbi.nlm.nih.gov/pubmed/29322257 http://dx.doi.org/10.1007/s00415-018-8732-z

Ejemplares similares

Zika virus and neurology: proving cause and effect
por: Massey, T. H., et al.
Publicado: (2016)

The economic burden of chronic neurological disease
por: Wynford-Thomas, R., et al.
Publicado: (2017)

MRI-guided focused ultrasound: new hope for drug-resistant neurological conditions
por: Bari, S., et al.
Publicado: (2023)

The gut microbiome: neurological development and disease
por: Miah, Latif, et al.
Publicado: (2022)

Why antisense could make sense for neurodegeneration
por: Massey, T. H., et al.
Publicado: (2017)

Restless legs syndrome: causes and consequences
por: Massey, T. H., et al.
Publicado: (2020)

Socioeconomic status in neurological disorders: a modifiable risk factor?
por: Hrastelj, J., et al.
Publicado: (2022)

Neurological complications of COVID-19: a preliminary review
por: Pryce-Roberts, A., et al.
Publicado: (2020)

Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2
por: Cauchi, M., et al.
Publicado: (2021)

Long-COVID: neurological manifestations and management
por: Williams, Sioned, et al.
Publicado: (2021)

Spontaneous intracranial hypotension: features, diagnosis and management
por: Massey, Tom H., et al.
Publicado: (2021)

Medication-overuse headache: causes, consequences and management
por: Massey, Thomas H., et al.
Publicado: (2021)

Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation
por: McLauchlan, D., et al.
Publicado: (2016)

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Treatments in Alzheimer’s disease
por: Malik, G. A., et al.
Publicado: (2017)

Creutzfeldt–Jacob disease: new directions in diagnosis and therapeutics
por: Al-Ansari, Aseel, et al.
Publicado: (2017)

Multiple sclerosis: early indicators of disease and assessing future risk
por: Willis, M. D., et al.
Publicado: (2020)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

New treatments in Alzheimer’s disease
por: Pickrell, William O., et al.
Publicado: (2018)

Seizures in Alzheimer’s disease: is there more beneath the surface?
por: Edwards, Marc, et al.
Publicado: (2017)

Stem cells in the treatment of central nervous system disease
por: McLauchlan, Duncan, et al.
Publicado: (2018)

New ways of looking at an old disease: the reimagination of epilepsy
por: Mitchell, Clinton J., et al.
Publicado: (2016)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies
por: Hrastelj, James, et al.
Publicado: (2017)

Sleep disorders in Parkinson’s disease
por: Hawken, Jonathan, et al.
Publicado: (2022)

The role of skin biopsy in differentiating idiopathic Parkinson’s disease from other types of parkinsonism
por: Wynford-Thomas, Ray, et al.
Publicado: (2015)

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders
por: Peall, K. J., et al.
Publicado: (2016)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Vaccine-induced immune thrombosis and thrombocytopaenia: incidence, mechanism and treatment
por: Hrastelj, J., et al.
Publicado: (2021)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

A role for the Epstein–Barr virus in multiple sclerosis aetiology?
por: Hrastelj, J., et al.
Publicado: (2022)

Clinical patterns in CADASIL
por: Gailani, G., et al.
Publicado: (2022)

Anti-epileptics and pregnancy: an update
por: Al-Ansari, A., et al.
Publicado: (2018)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Neurotoxicity of novel cancer immunotherapies
por: Willis, M. D., et al.
Publicado: (2019)

Dystonia: opportunities to gain insights into underlying pathophysiological mechanisms
por: Peall, K. J., et al.
Publicado: (2017)

Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis
por: Willis, M. D., et al.
Publicado: (2017)

B cell treatments for multiple sclerosis
por: McLauchlan, D., et al.
Publicado: (2017)

Autoimmune encephalitis: frequency and prognosis
por: Al-Ansari, A., et al.
Publicado: (2019)

Cerebral venous thrombosis: clinical predictors and emerging treatments
por: Al-Ansari, A., et al.
Publicado: (2020)

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2
por: Willis, M. D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qsulida084headpss8mdl6nqep